VNRX Volitionrx Ltd

  1. Stocks
  2. Healthcare
  3. NYSEAMERICAN: VNRX

Price (delayed)

$2.03

Market cap

$16.91M

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$4.17

Enterprise value

$25.51M

?
Relative Growth: Rel. Growth: 83
Relative Strength: Rel. Strength: 1
Relative Valuation: Rel. Valuation: 12
Relative Profitability: Rel. Profitability: 25

Volition is a multi-national epigenetics company developing simple, easy to use, costeffective blood tests to help diagnose a range of cancers and other diseases. Early diagnosis has the potential to ...

Highlights
The gross profit has soared by 88% YoY and by 43% QoQ
The revenue has surged by 88% year-on-year and by 43% since the previous quarter
The quick ratio has soared by 108% from the previous quarter but it has contracted by 26% YoY
The equity is down by 15% year-on-year but it is up by 7% since the previous quarter
VNRX's debt has soared by 59% YoY and by 2.1% QoQ
Volitionrx's net income has decreased by 5% from the previous quarter and by 2.4% YoY
Sector: Healthcare
Industry: Diagnostics & Research
Website: http://www.volitionrx.com
Peers: VIVS KEN

Key stats

What are the main financial stats of VNRX

VNRX stock price

How has the Volitionrx stock price performed over time
Intraday
-2.4%
1 week
-29.51%
1 month
-15.06%
1 year
-82.21%
YTD
-60.27%
QTD
-49.75%

Financial performance

How have Volitionrx's revenue and profit performed over time
Revenue
$2.47M
Gross profit
$2.47M
Operating income
-$21.57M
Net income
-$24.6M
Gross margin
100%
Net margin
-997.5%
The gross profit has soared by 88% YoY and by 43% QoQ
The revenue has surged by 88% year-on-year and by 43% since the previous quarter
The company's operating margin has surged by 53% YoY and by 31% QoQ
VNRX's net margin is up by 46% YoY and by 26% QoQ

Price vs fundamentals

How does VNRX's price correlate with its fundamentals

Growth

What is Volitionrx's growth rate over time

Valuation

What is Volitionrx stock price valuation
P/E
N/A
P/B
N/A
P/S
5.67
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
10.34
The company's EPS rose by 22% YoY and by 5% QoQ
The equity is down by 15% year-on-year but it is up by 7% since the previous quarter
The stock's P/S is 99% below its 5-year quarterly average of 508.8 and 83% below its last 4 quarters average of 34.0
The revenue has surged by 88% year-on-year and by 43% since the previous quarter

Efficiency

How efficient is Volitionrx business performance
The company's return on sales rose by 46% YoY and by 26% QoQ
Volitionrx's ROA has decreased by 44% YoY and by 3.6% from the previous quarter
Volitionrx's return on invested capital has decreased by 10% QoQ

Dividends

What is VNRX's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for VNRX.

Financial health

How did Volitionrx financials performed over time
The company's total assets is 79% lower than its total liabilities
The quick ratio has soared by 108% from the previous quarter but it has contracted by 26% YoY
VNRX's current ratio has soared by 94% since the previous quarter but it is down by 18% year-on-year
VNRX's debt is 137% higher than its equity
VNRX's debt has soared by 59% YoY and by 2.1% QoQ
The company's debt to equity fell by 37% YoY and by 12% QoQ

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.